Overview

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Status:
Terminated

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an immune response.

Phase:

Phase 3

Details

Lead Sponsor:

Lux Biosciences, Inc.

Treatments:

Cyclosporine
Cyclosporins